Submodule
Electrophysiologic Framework
Antiarrhythmic drugs modify excitable tissue whose behavior changes with cell type, channel state, heart rate, disease substrate, electrolyte environment, and autonomic tone.
- Mechanism and substrate
- State and use dependence
- Vaughan Williams limits
- Proarrhythmia
Treat instability first
Exclude unsafe agents
Predict concentration
Reassess the goal
Start with the tissue and the circuit
Fast-response atrial, His-Purkinje, and ventricular tissue depends heavily on sodium current for phase 0. Nodal tissue relies more on calcium current and autonomic signaling. Reentry, automaticity, and triggered activity therefore respond differently to the same drug.
Think in channel states and time
Many blockers prefer open or inactivated channels. Use dependence means effect grows with repeated activation, while reverse use dependence describes stronger repolarization delay at slower rates for some potassium-channel blockers. These kinetics explain why a resting ECG can underestimate exercise-related QRS widening or post-conversion QT risk.
Use Vaughan Williams as a map, not the territory
Class I emphasizes sodium block, class II beta blockade, class III repolarization delay, and class IV calcium-channel block. Individual agents can cross those boundaries. Sotalol adds beta blockade to IKr inhibition, propafenone has beta-blocking activity, and amiodarone has broad multichannel and antiadrenergic effects.
Name the expected harm before prescribing
Conduction slowing can create reentry or block. Repolarization delay can create torsades. Nodal suppression can produce bradycardia. Negative inotropy can worsen heart failure. The safe plan states the anticipated toxicity, how it will be measured, and what threshold changes treatment.
Quick check
Submodule
Sodium-Channel Blockers and Medicinal Chemistry
Class IA, IB, and IC drugs differ in channel recovery, tissue preference, secondary ion-channel effects, molecular access, metabolic pathways, and clinical substrate limits.
- Class IA and active metabolites
- Lidocaine and mexiletine
- Flecainide and propafenone
- Structure and ionization
QRS and QT
Lidocaine and mexiletine
Flecainide and propafenone
Access and binding
Recognize the local-anesthetic pharmacophore
Many sodium-channel blockers combine a hydrophobic aromatic region, a connecting linker, and an ionizable amine. Neutral species can cross lipid membranes, while protonated species often contribute strongly to channel binding. pKa, lipophilicity, stereochemistry, linker type, and metabolism alter onset, access, and persistence.
Separate IA parent and metabolite effects
Quinidine, procainamide, and disopyramide slow conduction and prolong repolarization. Procainamide forms active NAPA, whose potassium-channel effect and renal elimination can amplify QT risk. Quinidine adds interaction and gastrointestinal liabilities. Disopyramide adds negative inotropy and antimuscarinic effects.
Connect lidocaine chemistry to delivery
Lidocaine is an amide local-anesthetic scaffold used intravenously for selected ventricular arrhythmias. Its hepatic extraction makes reduced liver blood flow clinically important, and neurologic toxicity can signal excessive parent or metabolite exposure. Mexiletine retains related sodium-channel behavior but structural differences allow oral therapy, with gastrointestinal and neurologic dose limits.
Respect slow-recovery class IC block
Flecainide and propafenone strongly slow conduction, especially at faster rates. Prior MI, ischemic scar, or important structural disease makes this behavior dangerous. Propafenone also contributes beta blockade and CYP-sensitive exposure. In selected AF patients, AV nodal protection reduces the risk of rapid 1-to-1 atrial flutter conduction.
Quick check
Submodule
Potassium-Channel Blockers
Repolarization-active drugs can support conversion or maintenance of rhythm, but their benefit depends on disciplined QT, kidney, electrolyte, heart-rate, interaction, and telemetry management.
- IKr and reverse use dependence
- Dofetilide
- Sotalol
- Ibutilide
Renal dose and monitored start
Rate, kidney, QT
Post-dose telemetry
Prevent before treating
Understand pause-sensitive repolarization
IKr inhibition lengthens action-potential duration and QT. For several agents the effect can be greater at slow rates, making bradycardia and pauses especially important after conversion to sinus rhythm. Hypokalemia, hypomagnesemia, interacting QT drugs, and high exposure magnify early afterdepolarization risk.
Treat dofetilide initiation as a protocol
Dofetilide dosing follows calculated creatinine clearance and serial QT response. Initiation or reinitiation requires monitored care. Renal cation-transport inhibitors and other prohibited combinations can sharply raise exposure. Each dose decision must remain tied to the current label and institutional process.
Remember both halves of sotalol
Sotalol is a nonselective beta blocker and an IKr blocker. Bradycardia, bronchospasm risk, heart-failure status, renal elimination, QT prolongation, and other rate- or QT-active drugs all matter. Calling it only a beta blocker hides its major proarrhythmic mechanism.
Monitor after ibutilide conversion
IV ibutilide can convert selected atrial flutter or fibrillation, but polymorphic VT can occur during or after administration. Correct electrolytes, avoid inappropriate substrate, maintain continuous ECG observation for the label-defined period, and keep defibrillation immediately available.
Quick check
Submodule
Multichannel and Nodal Agents
Amiodarone, dronedarone, adenosine, beta blockers, calcium-channel blockers, and digoxin require different reasoning about channel breadth, autonomic effect, tissue distribution, clearance, and interaction burden.
- Amiodarone
- Dronedarone
- Adenosine
- AV nodal control
High efficacy, high surveillance
Distinct contraindications
AV nodal interruption
Match function and circuit
Treat amiodarone as an organ system drug
Amiodarone has sodium, potassium, calcium, and antiadrenergic effects. High lipophilicity and tissue distribution produce a long and variable terminal half-life. Loading, CYP and P-gp interactions, bradycardia, thyroid dysfunction, hepatic injury, pulmonary toxicity, eye and skin effects, and neurologic symptoms require indication-specific and longitudinal surveillance.
Do not call dronedarone safer amiodarone
Removing iodine and changing lipophilicity altered distribution and toxicity, but dronedarone has lower rhythm efficacy and distinct harm in permanent AF and recent decompensated or advanced symptomatic heart failure. Liver, heart-rate, QT, renal-marker, digoxin, and CYP3A considerations remain important.
Use adenosine as a transient diagnostic and therapeutic intervention
Adenosine acts at A1 receptors to transiently suppress AV nodal conduction. A proximal rapid bolus and flush are necessary because its plasma half-life is seconds. It can terminate AVNRT or orthodromic AVRT and can unmask atrial activity, but it is not a universal treatment for wide or irregular tachycardia.
Choose nodal control by physiology
Beta blockers reduce adrenergic nodal drive. Diltiazem and verapamil inhibit L-type calcium current but can worsen reduced systolic function. Digoxin enhances vagal nodal effect and may be weaker during high sympathetic tone. Additive bradycardia and block matter, and AV nodal blockers are dangerous in preexcited AF.
Quick check
Submodule
Substrate-Directed Clinical Selection
Rhythm control is a clinical strategy, not a drug reflex. Selection integrates symptoms, burden, circuit, ischemic scar, ventricular function, conduction reserve, stroke prevention, and ablation.
- AF maintenance
- Pill-in-the-pocket
- Structural heart disease
- Ablation and drug goals
Still screen ECG and organs
Protect against ventricular risk
Use proven pathways
Do not prolong failed toxicity
Define what rhythm control must accomplish
A drug may reduce episodes without eliminating them. The outcome can be symptom relief, improved ventricular function, fewer hospitalizations, reduced ICD therapies, or stabilization before ablation. Anticoagulation decisions remain tied to thromboembolic risk rather than apparent rhythm success.
Protect pill-in-the-pocket treatment with selection
Flecainide or propafenone single-dose treatment is for carefully selected recurrent AF after monitored first-dose safety and efficacy. Significant structural disease, conduction disease, bradycardia, and unsafe interactions must be excluded, and an AV nodal strategy is commonly required.
Let structural disease narrow the list
Prior MI, scar, reduced ejection fraction, significant hypertrophy, and decompensated heart failure change proarrhythmic and negative-inotropic risk. Class IC drugs are not routine choices in ischemic or significant structural disease. Other options remain drug and phenotype specific rather than universally safe.
Do not prolong failed toxicity
Contemporary AF care often supports earlier catheter ablation in suitable patients, while recurrent VT may require substrate ablation and ICD planning. Recurrence, dose-limiting toxicity, organ change, or patient preference should trigger a new strategy rather than automatic polypharmacy.
Quick check
Submodule
Monitoring, Interactions, and Longitudinal Safety
Antiarrhythmic safety depends on repeatable systems that connect dose and clearance to ECG change, electrolyte state, organ toxicity, drug interactions, rhythm benefit, and changing goals.
- Initiation protocols
- QT and QRS surveillance
- Pharmacokinetic interactions
- Longitudinal reassessment
Establish suitability
Catch early proarrhythmia
Measure benefit and burden
Change drug, ablate, or stop
Measure the interval the drug is expected to change
Sodium-channel block commonly widens PR or QRS, while repolarization-active therapy can prolong QT. Manual confirmation matters when tracings are noisy, paced, tachycardic, or wide. Compare with baseline and with the rate and concentration context rather than accepting one automated value.
Build exposure from organ function and interactions
Creatinine clearance can determine dosing or eligibility for dofetilide and sotalol. Hepatic metabolism and blood flow matter for lidocaine, propafenone, and amiodarone. Transporter and enzyme effects can alter digoxin, anticoagulants, and the antiarrhythmic itself. Pharmacodynamic overlap can be harmful even when concentrations do not change.
Use drug-specific surveillance
Amiodarone needs thyroid, liver, pulmonary, ocular, dermatologic, neurologic, and interaction review. Dofetilide and sotalol require QT, kidney, electrolyte, and bradycardia safeguards. Class IC drugs require conduction and substrate surveillance. Digoxin needs symptom, rhythm, kidney, electrolyte, timing, and interaction context.
Reassess benefit and alternatives
Document recurrence burden, symptoms, quality of life, hospital use, ventricular function, adverse effects, adherence, and patient goals. A new drug, acute illness, kidney decline, liver injury, pulmonary symptoms, syncope, or ECG change should reopen the entire risk-benefit decision.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.